Asuragen, Inc. Announces Collaboration on the Development of BCR-ABL1 RNA IS Calibrators and Laboratory Software Reporting Tool at American Society of Hematology

AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today that it has entered into an exclusive agreement with Novartis to develop worldwide Armored RNA Quant® (ARQ) BCR-ABL1 RNA International Scale (IS) Calibrators and laboratory software reporting tools, intended to aid laboratories with standardization of BCR-ABL1 RT-qPCR testing to the International Scale. As part of this agreement, Asuragen will develop and, if successful, distribute the ARQ BCR-ABL1 IS RNA Calibrators and software reporting tools to laboratories globally directly or through its distributors.

Back to news